Also Known As: HCTZ/Losartan, Hyzaar, Hydrochlorothiazide/losartan, Anzaplus
The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden.
In 2010, the patent for the combination expired, and Teva promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.